Efficacy and Safety of Rilzabrutinib in Patients With Chronic Spontaneous Urticaria: 12-Week Results From the RILECSU Phase 2 DoseRanging Study

被引：0
|
作者：
Maurer, Marcus [1 ]
Gimenez-Arnau, Ana [2 ]
Ferrucci, Silvia [3 ]
Mikol, Vincent [4 ]
Sun, Iris [5 ]
Mannent, Leda [4 ]
Gereige, Jessica [6 ]
机构：
[1] Charite Univ Med Berlin, Berlin, Germany
[2] Univ Pompeu Fabra, Hosp Mar & Res Inst, Barcelona, Spain
[3] Fdn IRCCS Ca Granda Osped Maggiore Policlin, SC Dermatol, Milan, Italy
[4] Sanofi, Chilly Mazarin, France
[5] Sanofi, Beijing, Peoples R China
[6] Sanofi, Cambridge, MA USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2024年 / 153卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
L38
引用
收藏
页码：AB373 / AB373
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of low-dose SoluMatrix meloxicam in the treatment of osteoarthritis pain: a 12-week, phase 3 study
    Altman, Roy
    Hochberg, Marc
    Gibofsky, Allan
    Jaros, Mark
    Young, Clarence
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (12) : 2331 - 2343
  • [42] REMIBRUTINIB IMPROVES CHRONIC SPONTANEOUS URTICARIA IN PATIENTS IRRESPECTIVE OF CU-INDEX: RESULTS FROM PHASE 2B STUDY
    Carr, W.
    Sitz, K.
    Jain, V.
    Gimenez-Arnau, A.
    Lheritier, K.
    Nikolaev, L.
    Haemmerle, S.
    Maurer, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S11 - S11
  • [43] Is there a need to switch retinoids to enhance results? Results from a 12-week comparative study
    Thiboutot, Diane M.
    Gardner, Sheila
    Colon, Luz E.
    Johnson, Lori A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB16 - AB16
  • [44] Safety and Efficacy Of a 12-Week Maintenance Interval In Patients Treated With Imported Fire Ant Immunotherapy
    Adams, Karla E.
    Stokes, Shayne
    White, Kevin M.
    Waibel, Kirk H.
    Tankersley, Michael S.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB18 - AB18
  • [45] Efficacy and safety of omalizumab against chronic spontaneous urticaria: Real-world study from China
    Wang, Ao
    Yun, Yuhui
    Wen, Zhihua
    Gao, Yingxia
    Qi, Shuzhen
    Zhang, Yu
    Liang, Yunsheng
    Yao, Xu
    WORLD ALLERGY ORGANIZATION JOURNAL, 2022, 15 (12):
  • [46] Long term safety and efficacy of ligelizumab in the treatment of Japanese patients with chronic spontaneous urticaria
    Takahashi, Hidetoshi
    Fukunaga, Atsushi
    Hayama, Koremasa
    Sasajima, Takayoshi
    Fujishige, Ayako
    Ichishita, Ryohei
    Tomimatsu, Naoko
    Hua, Eva
    Varanasi, Vineeth
    Burciu, Alis
    Hide, Michihiro
    Severin, Thomas
    ALLERGOLOGY INTERNATIONAL, 2025, 74 (01) : 136 - 143
  • [47] Efficacy and safety of ixekizumab, an interleukin-17A monoclonal antibody, in real-world patients with psoriasis: 12-week results from a Canadian multicenter retrospective study
    Georgakopoulos, Jorge R.
    Phung, Michelle
    Ighani, Arvin
    Yeung, Jensen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB120 - AB120
  • [48] Remibrutinib Treatment Improves Itch and Sleep in Chronic Spontaneous Urticaria Patients: Phase 2b Study Results
    Hsu, Connie
    Snyder, Robert
    Clore, Lee
    Jain, Vipul
    Gimenez-Arnau, Ana
    Lheritier, Karine
    Walsh, Pauline
    Haemmerle, Sibylle
    Wells, Michael
    Nikolaev, Ivan
    Maurer, Marcus
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB82 - AB82
  • [49] REMIBRUTINIB TREATMENT IMPROVES SLEEP AND ACTIVITY IN CHRONIC SPONTANEOUS URTICARIA PATIENTS: PHASE 2B STUDY RESULTS
    Clore, L.
    Jain, V.
    Gimenez-Arnau, A.
    Lheritier, K.
    Walsh, P.
    Haemmerle, S.
    Maurer, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S32 - S32
  • [50] REMIBRUTINIB TREATMENT IMPROVES HIVE SEVERITY IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA: PHASE 2B STUDY RESULTS
    Sitz, K.
    Gimenez-Arnau, A.
    Hayama, K.
    Jain, V.
    Lheritier, K.
    Walsh, P.
    Haemmerle, S.
    Maurer, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S11 - S11
12345